Role of connexins in infantile hemangiomas

Frontiers in Pharmacology

Volumn 4 APR, Issue , 2013, Pages

  Blanke, Katja ^a   Dähnert, Ingo ^a   Salameh, Aida ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Angiogenesis; Blood vessel; Connexins; Infantile hemangioma; Propranolol; adrenoceptor

Indexed keywords

GAP JUNCTION PROTEIN; GELATINASE A; GELATINASE B; PROPRANOLOL; RAF PROTEIN; RAS PROTEIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY HEMANGIOMA; CARDIOVASCULAR SYSTEM; CELL COMMUNICATION; EMBRYO DEVELOPMENT; HUMAN; MOLECULAR MECHANICS; ORGAN GROWTH; PATHOGENESIS;

EID: 84882960531     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00041     Document Type: Article

References (102)

1. Adams, D. M. (2001). The nonsurgical management of vascular lesions. Facial Plast. Surg. Clin. North Am. 9, 601-608.
2. Azzopardi, S., and Wright, T. C. (2012). Novel strategies for managing infantile hemangiomas: a review. Ann. Plast. Surg. 68, 226-228.
3. Barlow, C. F., Priebe, C. J., Mulliken, J. B., Barnes, P. D., MacDonald, D., Folkman, J., et al. (1998). Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J. Pediatr. 132, 527-530.
4. Boon, L. M., MacDonald, D. M., and Mulliken, J. B. (1999). Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr. Surg. 104, 1616-1623.
5. Brisset, A. C., Isakson, B. E., and Kwak, B. R. (2009). Connexins in vascular physiology and pathology. Antioxid. Redox Signal. 11, 267-282.
6. Bruckner, A. L., and Frieden, I. J. (2003). Hemangiomas of infancy. J. Am. Acad. Dermatol. 48, 477-493
7. Carmeliet, P (2003). Angiogenesis in health and disease. Nat. Med. 9, 653-660.
8. Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature 438, 932-936.
9. Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
10. Chadjichristos, C. E., Morel, S., Derouette, J. P., Sutter, E., Roth, I., Brisset, A. C., et al. (2008). Targeting connexin 43 prevents platelet-derived growth factor-BB-induced phenotypic change in porcine coronary artery smooth muscle cells. Circ. Res. 102, 653-660.
11. Chang, E., Boyd, A., Nelson, C. C., Crowley, D., Law, T., Keough, K. M., et al. (1997). Successful treatment of infantile hemangiomas with interferon-alpha-2b. J. Pediatr. Hematol. Oncol. 19, 237-244.
12. Chang, J., Most, D., Bresnick, S., Mehrara, B., Steinbrech, D. S., Reinisch, J., et al. (1999). Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast. Reconstr. Surg. 103, 1-9.
13. Chang, L. C., Haggstrom, A. N., Drolet, B. A., Baselga, E., Chamlin, S. L., Garzon, M. C., et al. (2008). Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 122, 360-367.
14. Chiller, K. G., Passaro, D., and Frieden, I. J. (2002). Hemangiomas of infancy: clinical charcteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch. Dermatol. 138, 1567-1576.
15. Chim, H., Armijo, B. S., Miller, E., Gliniak, C., Serret, M. A., and Gosain, A. K. (2012). Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann. Surg. 256, 146-156.
16. Cohen, S. R., and Wang, C. I. (1972). Steroid treatment of hemangioma of the head and neck in children. Ann. Otol. Rhinol. Laryngol. 81, 584-590.
17. Conway, E. M., Collen, D., and Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49, 507-521.
18. Coutinho, P., Qiu, C., Frank, S., Tamber, K., and Becker, D. (2003). Dynamic changes in connexin expression correlate with key events in the wound healing process. Cell Biol. Int. 27, 525-541.
19. Czyz, J. (2008). The stage-specific function of gap junctions during tumourigenesis. Cell. Mol. Biol. Lett. 13, 92-102.
20. D'Angelo, G., Lee, H., and Weiner, R. I. (1997). cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J. Cell. Biochem. 67, 353-366.
21. Delmar, M., and Makita, N. (2012). Cardiac connexins, mutations and arrhythmias. Curr. Opin. Cardiol. 27, 236-241.
22. De Wit, C. (2004). Connexins pave the way for vascular communication. News Physiol. Sci. 19, 148-153.
23. Dhein, S., Polontchouk, L., Salameh, A., and Haefliger, J. A. (2002). Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexion 40. Biol. Cell 94, 409-422.
24. Drolet, B. A., Esterly, N. B., and Frieden, I. J. (1999). Hemangiomas in children. N. Engl. J. Med. 341, 173-181.
25. Drolet, B. A., Swanson, E. A., Frieden, I. J., and Hemangioma Investigator Group. (2008). Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J. Pediatr. 153, 712-715.
26. Dupays, L., Mazurais, D., Rücker-Martin, C., Calmels, T., Bernot, D., Cronier, L., et al. (2003). Genomic organization and alternative transcripts of the human Connexin40 gene. Gene 305, 79-90.
27. Eichmann, A., Yuan, L., Moyon, D., Lenoble, F., Pardanaud, L., and Breant, C. (2005). Vascular development: from precursor cells to branched arterial and venous networks. Int. J. Dev. Biol. 49, 259-267.
28. Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., and Cheresh, D. A. (1999). Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4, 915-924.
29. Figueroa, X. F., and Duling, B. R. (2009). Gap junctions in the control of vascular function. Antioxid. Redox Signal. 11, 251-266.
30. Finn, M. C., Glowacki, J., and Mulliken, J. B. (1983). Congenital vascular lesions: clinical application of a new classification. J. Pediatr. Surg. 18, 894-900.
31. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
32. Gabriels, J. E., and Paul, D. L. (1998). Connexin43 is highly localized to sites of disturbed flow in rat aortic endothelium but connexin37 and connexin40 are more uniformly distributed. Circ. Res. 83, 636-643.
33. Gärtner, C., Ziegelhöffer, B., Kostelka, M., Stepan, H., Mohr, F. W., and Dhein, S. (2012). Knock-down of endothelial connexins impairs angiogenesis. Pharmacol. Res. 65, 347-357.
34. Geletu, M., Trotman-Grant, A., and Raptis, L. (2012). Mind the gap; regulation of gap junctional, intercellular communication by the SRC oncogene product and its effectors. Anticancer Res. 32, 4245-4250.
35. Greenberger, S., and Bischoff, J. (2011). Infantile hemangioma-mechanism(s) of drug action on a vascular tumor. Cold Spring Harb. Perspect. Med. 1, a006460.
36. Guimarães, S., and Moura, D. (2001). Vascular adrenoceptors: an update. Pharmacol. Rev. 53, 319-356.
37. Haefliger, J. A., Nicod, P., and Meda, P. (2004). Contribution of connexins to the function of the vascular wall. Cardiovasc. Res. 62, 345-356.
38. Harris, S. R., Schoeffner, D. J., Yoshiji, H., and Thorgeirsson, U. P. (2002). Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett. 179, 95-101.
39. Hemangioma Investigator Group, Haggstrom, A. N., Drolet, B. A., Baselga, E., Chamlin, S. L., Garzon, M. C., et al. (2007). Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J. Pediatr. 150, 291-294.
40. Hill, C. E., Phillipps, J. K., and Sandow, S. L. (2001). Heterogeneous control of blood flow amongst different vascular beds. Med. Res. Rev. 21, 1-60.
41. Hochman, M., Adams, D. M., and Reeves, T. D. (2011). Current knowledge and management of vascular anomalies: infantile hemangiomas. Arch. Facial Plast. Surg. 13, 145-151.
42. Holmes, W. J., Mishra, A., Gorst, C., and Liew, S. H. (2011). Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J. Plast. Reconstr. Aesthet. Surg. 64, 445-451.
43. Hu, H. T., Ma, Q. Y., Zhang, D., Shen, S. G., Han, L., Ma, Y. D., et al. (2010). HIF-1alpha links beta-adrenoceptor agonists and pancreatic cancer cells under normoxic condition. Acta Pharmacol. Sin. 31, 102-110.
44. Iaccarino, G., Ciccarelli, M., Sorriento, D., Galasso, G., Campanile, A., Santulli, G., et al. (2005). Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ. Res. 97, 1182-1189.
45. Isakson, B. E., Best, A. K., and Duling, B. R. (2008). Incidence of protein on actin bridges between endothelium and smooth muscle in arterioles demonstrates heterogeneous connexin expression and phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 294, H2898-H2904.
46. Isakson, B. E., Damon, D. N., Day, K. H., Liao, Y., and Duling, B. R. (2006). Connexin40 and connexin43 in mouse aortic endothelium: evidence for coordinated regulation. Am. J. Physiol. Heart Circ. Physiol. 290, H1199-H1205.
47. Jamieson, S., Going, J. J., D'Arcy, R., and George, W. D. (1998). Expression of gap junction proteins connexin 26 and connexin 43 in normal human breast and in breast tumours. J. Pathol. 184, 37-43.
48. Ji, Y., Chen, S., Li, K., Xiao, X., Zheng, S., and Xu, T. (2013). The role of beta-adrenergic receptor signaling in the proliferation of hemangiomas-derived endothelial cells. Cell Div. 8, 1.
49. Johnstone, S., Isakson, B., and Locke, D. (2009). Biological and biophysical properties of vascular connexin channels. Int. Rev. Cell Mol. Biol. 278, 69-118.
50. Johnstone, S. R., Kroncke, B. M., Straub, A. C., Best, A. K., Dunn, C. A., Mitchell, L. A., et al. (2012). MAPK phosphorylation of connexin 43 promotes binding of cyclin E and smooth muscle cell proliferation. Circ. Res. 111, 201-211.
51. Kar, R., Batra, N., Riquelme, M. A., and Jiang, J. X. (2012). Biological role of connexin intercellular channels and hemichannels. Arch. Biochem. Biophys. 524, 2-15.
52. Kieran, M. W., Kalluri, R., and Cho, Y. J. (2012). The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb. Perspect. Med. 2, a006593.
53. Kleinman, M. E., Greives, M. R., Churgin, S. S., Blechman, K. M., Chang, E. I., Ceradini, D. J., et al. (2007). Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler. Thromb. Vasc. Biol. 27, 2664-2670.
54. Ko, Y. S., Yeh, H. I., Rothery, S., Dupont, E., Coppen, S. R., and Severs, N. J. (1999). Connexin make-up of endothelial gap junctions in the rat pulmonary artery as revealed by immunoconfocal microscopy and triple-label immunogold electron microscopy. J. Histochem. Cytochem. 47, 683-692.
55. Krüger, O., Plum, A., Kim, J. S., Winterhager, E., Maxeiner, S., Hallas, G., et al. (2000). Defective vascular development in connexin 45-deficient mice. Development 127, 4179-4193.
56. Laird, D. W. (2006). Life cycle of connexins in health and disease. Biochem. J. 394, 527-543.
57. Léauté-Labrèze, C., Dumas de la Roque, E., Hubiche, T., Boralevi, F., Thambo, J. B., and Taïeb, A. (2008). Propranolol for severe hemangiomas of infancy. N. Engl. J. Med. 358, 2649-2651.
58. Li, X., and Simard, J. M. (2001). Connexin45 gap junction channels in rat cerebral vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 281, H1890-H1898.
59. Liao, Y., Regan, C. P., Manabe, I., Owens, G. K., Day, K. H., Damon, D. N., et al. (2007). Smooth muscle-targeted knockout of connexin43 enhances neointimal formation in response vascular injury. Arterioscler. Thromb. Vasc. Biol. 27, 1037-1042.
60. Little, T. L., Beyer, E. C., and Duling, B. R. (1995). Connexin 43 and connexin 40 gap junctional proteins are present in arteriolar smooth-muscle and endothelium in vivo. Am. J. Physiol. 268, H729-H739.
61. Maguiness, S. M., and Frieden, I. J. (2012). Management of difficult infantile hemangiomas. Arch. Dis. Child. 97, 266-271.
62. Marano, G., Palazzesi, S., Fadda, A., Vergari, A., and Ferrari, A. U. (2002). Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of beta-adrenoceptor blockade. J. Hypertens. 20, 763-769.
63. Margileth, A. M., and Museles, M. (1965). Cutaneous hemangiomas in children: diagnosis and conservative management. JAMA 194, 523-526.
64. Martínez, A. D., Acuña, R., Figueroa, V., Maripillan, J., and Nicholson, B. (2009). Gap-junction channels dysfunction in deafness and hearing loss. Antioxid. Redox Signal.11, 309-322.
65. Mayer, M., Minichmayr, A., Klement, F., Hroncek, K., Wertaschnigg, D., Arzt, W., et al. (2012). Tocolysis with the β-2-sympathomimetic hexoprenaline increases occurrence of infantile haemangioma in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 98, F2-F4.
66. Mentzel, T., Calonje, E., and Fletcher, C. D. (1994). Vascular tumors of the skin and soft tissue: overview of newly characterized entities and variants. Pathologe 15, 259-270.
67. Mulliken, J. B., and Glowacki, J. (1982). Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast. Reconstr. Surg. 69, 412-422.
68. Naus, C. C., Bechberger, J. F., Caveney, S., and Wilson, J. X. (1991). Expression of gap junction genes in astrocytes and C6 glioma cells. Neurosci. Lett. 126, 33-36.
69. Neri, I., Balestri, R., and Patrizi, A. (2012). Heamangiomas: new insight and medical treatment. Dermatol. Ther. 25, 322-334.
70. Pagès, G., Milanini, J., Richard, D. E., Berra, E., Gothié, E., Viñals, F., et al. (2000). Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann. N. Y. Acad. Sci. 902, 187-200.
71. Pahujaa, M., Anikin, M., and Goldberg, G. S. (2007). Phosphorylation of connexin43 induced by Src: regulation of gap junctional communication between transformed cells. Exp. Cell Res. 313, 4083-4090.
72. Parenti, A., Morbidelli, L., Cui, X. L., Douglas, J. G., Hood, J. D., Granger, H. J., et al. (1998). Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. 273, 4220-4226.
73. Paznekas, W. A., Karczeski, B., Vermeer, S., Lowry, R. B., Delatycki, M., Laurence, F., et al. (2009). GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Hum. Mutat. 30, 724-733.
74. Phung, T. L., Hochman, M., and Mihm, M. C. (2005). Current knowledge of the pathogenesis of infantile hemangiomas. Arch. Facial Plast. Surg. 7, 319-321.
75. Przewratil, P., Sitkiewicz, A., and Andrzejewska, E. (2010). Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. Cytokine 49, 141-147.
76. Przewratil, P., Sitkiewicz, A., Wyka, K., and Andrzejewska, E. (2009). Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations - preliminary report. Pediatr. Dermatol. 26, 399-404.
77. Razon, M. J., Kräling, B. M., Mulliken, J. B., and Bischoff, J. (1998). Increased apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation 5, 189-195.
78. Ricketts, R. R., Hatley, R. M., Corden, B. J., Sabio, H., and Howell, C. G. (1994). Interferon-alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann. Surg. 219, 605-612.
79. Ritter, M. R., Dorrell, M. I., Edmonds, J., Friedlnder, S. F., and Friedlander, M. (2002). Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc. Natl. Acad. Sci. U.S.A. 99, 7455-7460.
80. Rummery, N. M., Hickey, H., McGurk, G., and Hill, C. E. (2002). Connexin37 is the major connexin expressed in the media of caudal artery. Arterioscler. Thromb. Vasc. Biol. 22, 1427-1432.
81. Sakurai, T., and Kudo, M. (2011). Signaling pathways governing tumor angiogenesis. Oncology 81(Suppl. 1), 24-29.
82. Salameh, A., Blanke, K., Dhein, S., and Janousek, J. (2010). Cardiac gap junction channels are upregulated by metoprolol: an unexpected effect of beta-blockers. Pharmacology 85, 203-210.
83. Salameh, A., Krautblatter, S., Karl, S., Blanke, K., Gomez, D. R., Dhein, S., et al. (2009). The signal transduction cascade regulating the expression of the gap junction protein connexin43 by beta-adrenoceptors. Br. J. Pharmacol. 158, 198-208.
84. Saunders, M. M., Seraj, M. J., Li, Z., Zhou, Z., Winter, C. R., Welch, D. R., et al. (2001). Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res. 61, 1765-1767.
85. Scherer, S. S., and Kleopa, K. A. (2012). X-linked Charcot-Marie-Tooth disease. J. Peripher. Nerv. Syst. 17(Suppl. 3), 9-13.
86. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
87. Severs, N. J., Rothery, S., Dupont, E., Coppen, S. R., Yeh, H. I., Ko, Y. S., et al. (2001). Immunocytochemical analysis of connexin expression in the healthy and diseased cardiovascular system. Microsc. Res. Tech. 52, 301-322.
88. Simon, A. M., and McWhorter, A. R. (2002). Vascular abnormalities in mice lacking the endothelial gap junction proteins connexin37 and connexin40. Dev. Biol. 251, 206-220.
89. Simon, A. M., and McWorther, A. R. (2003). Decreased intercellular dye-transfer and downregulation of non-ablated connexins in aortic endothelium deficient in connexin37 or connexin40. J. Cell Sci. 116, 2223-2236.
90. Söhl, G., and Willecke, K. (2004). Gap junctions and the connexin protein family. Cardiovasc. Res. 62, 228-232.
91. Starkey, E., and Shahidullah, H. (2011). Propranolol for infantile hemangiomas: a review. Arch. Dis. Child. 96, 890-893.
92. Storch, C. H., and Hoeger, P. H. (2010). Propranolol for infantile hemangiomas: insights into the molecular mechanisms of action. Br. J. Dermatol. 163, 269-274.
93. Takahashi, K., Mulliken, J. B., Kozakewich, H. P., Rogers, R. A., Folkman, J., and Ezekowitz, R. A. (1994). Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest. 93, 2357-2364.
94. Tamayo, L., Ortiz, D. M., Orozco-Covarrubias, L., Durán-McKinster, C., Mora, M. A., Avila, E., et al. (1997). Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch. Dermatol. 133, 1567-1571.
95. van Kempen, M. J., and Jongsma, H. J. (1999). Distribution of connexin37, connexin40 and connexin43 in the aorta and coronary artery of several mammals. Histochem. Cell Biol. 112, 479-486.
96. Warn-Cramer, B. J., Lampe, P. D., Kurata, W. E., Kanemitsu, M. Y., Loo, L. W., Eckhart, W., et al. (1996). Characterization of the mitogen-activated protein kinase phosphorylation sites on the connexin-43 gap junction protein. J. Biol. Chem. 271, 3779-3786.
97. Wirth, F. A., and Lowitt, M. H. (1998). Diagnosis and treatment of cutaneous vascular lesions. Am. Fam. Physician 57, 765-773.
98. Yamasaki, H., Krutovskikh, V., Mesnil, M., Tanaka, T., Zaidan-Dagli, M. L., and Omori, Y. (1999). Role of connexin (gap junction) genes in cell growth control and carcinogenesis. C. R. Acad. Sci. III 322, 151-159.
99. Yeh, H. I., Rothery, S., Dupont, E., Coppen, S. R., and Severs, N. J. (1998). Individual gap junction plaques contain multiple connexins in arterial endothelium. Circ. Res. 83, 1248-1263.
100. Zhang, D., Ma, Q., Shen, S., and Hu, H. (2009). Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell. Pancreas 38, 94-100.
101. Zhang, W., DeMattia, J. A., Song, H., and Couldwell, W. T. (2003). Communication between malignant glioma cells and vascular endothelial cells through gap junctions. J. Neurosurg. 98, 846-853.
102. Zhong, S., Yang, G., Xia, C., Duanlian, Z., and Shan, S. (2009). Expression of matrix metalloproteinase and its tissue inhibitor in haemangioma. J. Huazhong Univ. Sci. Technolog. Med. Sci. 29, 614-619.